JP2019518041A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518041A5
JP2019518041A5 JP2018565337A JP2018565337A JP2019518041A5 JP 2019518041 A5 JP2019518041 A5 JP 2019518041A5 JP 2018565337 A JP2018565337 A JP 2018565337A JP 2018565337 A JP2018565337 A JP 2018565337A JP 2019518041 A5 JP2019518041 A5 JP 2019518041A5
Authority
JP
Japan
Prior art keywords
substituted
independently
alkyl
heterocyclyl
dimethoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018565337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518041A (ja
JP6962941B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/037370 external-priority patent/WO2017218617A1/en
Publication of JP2019518041A publication Critical patent/JP2019518041A/ja
Publication of JP2019518041A5 publication Critical patent/JP2019518041A5/ja
Application granted granted Critical
Publication of JP6962941B2 publication Critical patent/JP6962941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018565337A 2016-06-14 2017-06-14 Apj受容体アゴニストとしての4−ヒドロキシ−3−スルホニルピリジン−2(1h)−オン Active JP6962941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349719P 2016-06-14 2016-06-14
US62/349,719 2016-06-14
PCT/US2017/037370 WO2017218617A1 (en) 2016-06-14 2017-06-14 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists

Publications (3)

Publication Number Publication Date
JP2019518041A JP2019518041A (ja) 2019-06-27
JP2019518041A5 true JP2019518041A5 (enExample) 2020-09-17
JP6962941B2 JP6962941B2 (ja) 2021-11-05

Family

ID=59091682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018565337A Active JP6962941B2 (ja) 2016-06-14 2017-06-14 Apj受容体アゴニストとしての4−ヒドロキシ−3−スルホニルピリジン−2(1h)−オン

Country Status (7)

Country Link
US (1) US10889565B2 (enExample)
EP (1) EP3468952B1 (enExample)
JP (1) JP6962941B2 (enExample)
KR (1) KR102521955B1 (enExample)
CN (1) CN109641843B (enExample)
ES (1) ES2844184T3 (enExample)
WO (1) WO2017218617A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY189453A (en) 2015-06-03 2022-02-14 Bristol Myers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
CA3001974A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
WO2017096130A1 (en) 2015-12-04 2017-06-08 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
TW201725203A (zh) 2015-12-16 2017-07-16 必治妥美雅史谷比公司 作為apj受體促效劑之雜芳基羥基嘧啶酮
MA43761A (fr) 2016-03-24 2021-05-05 Bristol Myers Squibb Co 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10508104B2 (en) 2016-06-14 2019-12-17 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists
EP3526198B1 (en) * 2016-10-14 2020-08-12 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists
MA46827A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
ES2974842T3 (es) * 2018-11-13 2024-07-01 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
WO2020102100A1 (en) 2018-11-13 2020-05-22 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847927A (en) * 1972-12-20 1974-11-12 Dow Chemical Co Sulfur-containing hydroxypyridones
DK0729463T3 (da) * 1993-11-19 2002-09-09 Parke Davis & Co 5,6-Dihydropyronderivater som proteaseinhibitorer og antivirale midler
WO1995014014A2 (en) * 1993-11-19 1995-05-26 Parke, Davis & Company Pyrone derivatives as protease inhibitors and antiviral agents
US5691335A (en) * 1994-07-29 1997-11-25 Suntory Limited Imidazolidine derivative and use thereof
JP3537231B2 (ja) * 1995-07-24 2004-06-14 第一サントリーファーマ株式会社 ヒダントイン誘導体およびその用途
US10570128B2 (en) 2014-05-28 2020-02-25 Sanford Burnham Prebys Medical Discovery Institute Agonists of the apelin receptor and methods of use thereof
MY189453A (en) * 2015-06-03 2022-02-14 Bristol Myers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
CA3001974A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
WO2017096130A1 (en) 2015-12-04 2017-06-08 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
TW201725203A (zh) 2015-12-16 2017-07-16 必治妥美雅史谷比公司 作為apj受體促效劑之雜芳基羥基嘧啶酮
MA43761A (fr) 2016-03-24 2021-05-05 Bristol Myers Squibb Co 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj
US10508104B2 (en) 2016-06-14 2019-12-17 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists
EP3526198B1 (en) 2016-10-14 2020-08-12 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists

Similar Documents

Publication Publication Date Title
JP2019518041A5 (enExample)
JP2019532072A5 (enExample)
JP2019518036A5 (enExample)
JP6545199B2 (ja) 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類
ES2817902T3 (es) N-acil-N'-(piridin-2-il) ureas y análogos que presentan actividades anticancerosas y antiproliferativas
RU2429236C2 (ru) Новая полиморфная форма и аморфная форма 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида
CN102056923B (zh) 利伐沙班和丙二酸的新的共晶体化合物
JP2019517475A5 (enExample)
JP2019094350A (ja) 抗癌活性及び抗増殖活性を呈する2−アミノピリミジン−6−オン及び類似体
IL259947A (en) The troirylhydroxypyrimidinones as apj receptor agonists
CA2709786A1 (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof
ES2749682T3 (es) Derivados de pirazolona como donadores de nitroxilo
JP2004506718A5 (enExample)
JP6646044B2 (ja) キナーゼ阻害剤としての化合物および組成物
CA2723559A1 (en) 1,4-diaryl-pyrimidopyridazine-2,5-diones and their use
US20040242648A1 (en) Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
EA025863B1 (ru) Карбазолкарбоксамидные соединения
JP2016535769A5 (enExample)
CA2446879A1 (en) 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
JP2008523103A (ja) Erkプロテインキナーゼのピリミジンインヒビターおよびその使用
JP2019522628A5 (enExample)
US9096531B2 (en) Fused imidazole derivative
KR100642231B1 (ko) 2-티오-치환 이미다졸 유도체류 및 제약에서의 그 용도
CN112638884B (zh) 三唑磺酰胺衍生物及其制备方法和应用
AU2015273578B2 (en) Small molecule LFA-1 inhibitors